PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
49.00%
EBIT growth above 1.5x AVXL's 0.89%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
-9.04%
Negative operating income growth while AVXL is at 0.89%. Joel Greenblatt would press for urgent turnaround measures.
48.96%
Positive net income growth while AVXL is negative. John Neff might see a big relative performance advantage.
53.59%
Positive EPS growth while AVXL is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
51.99%
Positive diluted EPS growth while AVXL is negative. John Neff might view this as a strong relative advantage in controlling dilution.
10.21%
Share change of 10.21% while AVXL is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
6.42%
Diluted share change of 6.42% while AVXL is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
-59.54%
Negative OCF growth while AVXL is at 75.10%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-60.23%
Negative FCF growth while AVXL is at 75.10%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7534.43%
Negative 10Y OCF/share CAGR while AVXL stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-15675.30%
Negative 5Y OCF/share CAGR while AVXL is at 96.48%. Joel Greenblatt would question the firm’s operational model or cost structure.
-5709.37%
Negative 3Y OCF/share CAGR while AVXL stands at 97.95%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-6744.35%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-20067.21%
Negative 5Y net income/share CAGR while AVXL is 94.09%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-6838.40%
Negative 3Y CAGR while AVXL is 94.59%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
530.49%
Positive 5Y equity/share CAGR while AVXL is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
431.75%
3Y equity/share CAGR above 1.5x AVXL's 65.82%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-29.38%
Negative asset growth while AVXL invests at 614.58%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-71.36%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-100.00%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
52.82%
R&D dropping or stable vs. AVXL's 6868.04%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-14.04%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.